Back to News
Market Impact: 0.3
AbbVie Secures EU Approval For RINVOQ In Children With Juvenile Arthritis
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
The European Commission approved AbbVie's RINVOQ for active polyarticular juvenile idiopathic arthritis in children aged two years and older who have had an inadequate response or intolerance to one or more disease-modifying therapies. The approval expands RINVOQ's European pediatric treatment addressable market and supports AbbVie's immunology growth strategy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
ABBV0.70
More News
- AbbVie’s Rinvoq gains EU approval for juvenile arthritis
- Trump Says US Team Met With Iranians at UNGA
- Paramount will need to release way more movies to make this merger work
- Sullivan: Wall Street admits it doesn't know where oil is headed. There's one stock they do agree on
- U.S. regulators rush to write crypto rulebook after Clarity Act stalls in Senate
- Heidi CEO on AI in Healthcare, $900M valuation